Impact of gefitinib ('Iressa') treatment on the quality of life of patients with advanced non-small-cell lung cancer

Journal of Cancer Research and Clinical Oncology

Volumn 131, Issue 12, 2005, Pages 783-788

  Gelibter, Alain ^a   Ceribelli, Anna ^a   Pollera, Camillo F ^b   Milella, Michele ^a   Moscetti, Luca ^b   Sperduti, Isabella ^a   Cognetti, Francesco ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b BELCOLLE HOSPITAL   (Italy)

Author keywords

Gefitinib ('Iressa'); Non small cell lung cancer; Quality of life

Indexed keywords

GEFITINIB;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DYSPNEA; EVIDENCE BASED MEDICINE; FATIGUE; FEMALE; HEMOPTYSIS; HUMAN; INSOMNIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RASH;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; CONSTIPATION; DISEASE PROGRESSION; DYSPNEA; FATIGUE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; QUINAZOLINES; SLEEP INITIATION AND MAINTENANCE DISORDERS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 27744580315     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-005-0029-9     Document Type: Article

References (20)

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJ, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376
2. American Society of Clinical Oncology (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671-679
3. Armstrong BG, Sloan M (1989) Ordinal regression models for epidemiologic data. Am J Epidemiol 129:191-204
4. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M (1994) The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 30A:635-642
5. Berridge DM, Whitehead J (1991) Analysis of failure time data with ordinal categories of response. Stat Med 10:1703-1710
6. Dancey J, Shepherd FA, Gralla RJ, Kim YS (2004) Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 43:183-194
7. Douillard J-Y, Giaccone G, Horai T, Noda K, Vansteenkiste JF, Takata I, Gatzemeier U, Fukuoka M, Macleod A, Feyereislova A, Averbuch S, Nogi Y, Heyes A, Baselga J (2002) Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1). Proc Am Soc Clin Oncol 21:299a (abs 1195)
8. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L (2000) The TAX 320 Non-Small Cell Lung Cancer Study Group: randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18:2354-2362
9. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J-Y, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong R-P, Baselga J (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246
10. Kaplan EL, Meier P (1958) Non parametric estimation from incomplete observation. J Am Stat Assoc 53:457-481
11. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 290:2149-2158
12. Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR (2001) Quality of life in lung cancer patients as an important prognostic factor. Lung Cancer 31:233-240
13. Natale RB, Zaretsky SL (2002) ZD1839 (Iressa™): what's in it for the patient?. Oncologist 7(Suppl 4):25-30
14. Natale R, Skarin A, Maddox A, Hammond L, Thomas R, Gandara D, Gerstein H, Panella T, Cole J, Jahanzeb M, Kash J, Hamm J, Langer C, Saleh M, Stella P, Heyes A, Helms L, Ochs J, Averbuch S, Wolf M, Kay A (2002) Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. Proc Am Soc Clin Oncol 21:292a (abs 1167)
15. Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144
16. Rowinsky EK (2001) EGFR-targeted cancer therapies: Is there a need to reconsider clinical trial design? A discussion of how, and why, clinical trial design should be altered for the clinical evaluation of EGRF-targeted cancer therapies. Signal 2:4-12
17. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103
18. Silvestri G, Pritchard R, Welch HG (1998) Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 317:771-775
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
20. WHO (1979) Handbook for reporting results in cancer treatment. World Health Organization, Geneva